Facing off with the FTC isn't for the timid. But when your mission and your business model are aligned, the hard decisions – about risk, about investment, about priorities – become clearer. Francis deSouza is CEO of Illumina, the world’s dominant maker of gene sequencing technology. After playing a key role in the creation of Covid vaccines, Illumina is trying to acquire a company with a breakthrough cancer screening test, over the FTC's objections. DeSouza offers a personal reflection on the lessons and reality of grappling with regulators, highlighting levers that can help to accelerate scale. What underscores his entrepreneurial efforts is a passion for Illumina’s mission: improving human health by unlocking the power of the genome.Read a transcript of this interview at: mastersofscale.comSubscribe to the Masters of Scale weekly newsletter at http://eepurl.com/dlirtXSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.